Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Immunic, Inc. (IMUX) had Consolidated Net Income/Loss of $-32.59M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-32.59M |
|
-- |
|
-- |
|
$33.23M |
|
$-33.23M |
|
$0.65M |
|
$-32.59M |
|
$-32.59M |
|
$-32.59M |
|
$-32.59M |
|
|
Consolidated Net Income/Loss |
$-32.59M |
$-32.59M |
|
$-33.23M |
|
$-33.20M |
|
30.14M |
|
30.14M |
|
$-1.08 |
|
$-1.08 |
|
| Balance Sheet Financials | |
$188.76M |
|
$0.57M |
|
$0.98M |
|
$189.74M |
|
$38.36M |
|
-- |
|
$0.15M |
|
$38.51M |
|
$151.23M |
|
$151.23M |
|
$151.23M |
|
13.62M |
|
| Cash Flow Statement Financials | |
$-17.30M |
|
$-0.00M |
|
$188.64M |
|
$15.48M |
|
$186.63M |
|
$171.15M |
|
$4.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.55% |
|
-21.55% |
|
-17.17% |
|
-21.55% |
|
$11.10 |
|
$-0.57 |
|
$-0.57 |
|